Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 169,497,434 | 31,560,247 | 42,290,773 | 257,200,000 | 33,185,000 | 533,733,454 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 169,497,434 | 31,560,247 | 42,290,773 | 257,200,000 | 33,185,000 | 533,733,454 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 169,262,313 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 364,471,141 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 169,497,434 | 31,560,247 | 42,290,773 | 257,200,000 | 33,185,000 | 533,733,454 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 90,780,000 | 70,401,294 | 34,044,000 | 10,141,000 | 82,829 | 205,449,123 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | |||||
| 11 | Total support. Add lines 7 through 10 | 739,182,577 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2018 | (b) 2019 | (c) 2020 | (d) 2021 | (e) 2022 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2022 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2022 |
(iii) Distributable Amount for 2022 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2022 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2022: | ||||
| a From 2017....... | ||||
| b From 2018....... | ||||
| c From 2019....... | ||||
| d From 2020....... | ||||
| e From 2021....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2022 distributable amount | ||||
|
i
Carryover from 2017 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2022 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2022 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2023. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2018..... | ||||
| b Excess from 2019..... | ||||
| c Excess from 2020..... | ||||
| d Excess from 2021..... | ||||
| e Excess from 2022..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| PART I, LINE 3 | THE INTERNAL REVENUE SERVICE HAS DETERMINED THAT MEMORIAL SLOAN-KETTERING CANCER CENTER QUALIFIES AS A PUBLIC CHARITY UNDER SECTION 170 (B) (1) (A) (iii). HOWEVER, SINCE IT DOES NOT OPERATE A HOSPITAL, IT IS NOT REQUIRED TO COMPLETE SCHEDULE H. |
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| NOTE A - AFFILIATED ORGANIZATIONS | MEMORIAL SLOAN-KETTERING CANCER CENTER (THE CENTER) IS AFFILIATED WITH THE FOLLOWING 501 (C) (3) ORGANIZATIONS: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (THE INSTITUTE), MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (THE HOSPITAL), S.K.I. REALTY, INC., MSK INSURANCE US, INC., THE LOUIS V. GERSTNER JR., GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, MSKCC PROPERTIES LLC, WITH THE HOSPITAL BEING THE SOLE MEMBER, THE PROSTATE CANCER CLINICAL TRIALS CONSORTIUM (PCCTC) AND MSKCC PROTON INC. WITH THE CENTER BEING THE SOLE MEMBER. THE ORGANIZATIONS SHARE CERTAIN FACILITIES AND VARIOUS SERVICES INCLUDING ADMINISTRATIVE, PLANT AND ANCILLARY SERVICES. THE FOLLOWING IS A SUMMARY OF SUCH SERVICES AMOUNTS IN 2022: SERVICES PROVIDED TO THE CENTER BY: THE HOSPITAL $ 18,311,000 THE INSTITUTION $ 8,647,000 S.K.I. REALTY, INC. $ 7,546,000 TOTAL $ 34,504,000 SERVICES PROVIDED BY THE CENTER TO: THE HOSPITAL $ 971,281,000 THE INSTITUTION $ 245,778,000 S.K.I. REALTY, INC. $ 6,297,000 GERSTNER GRADUATE SCHOOL $ 42,000 TOTAL $ 1,223,398,000 MEMORIAL SLOAN-KETTERING CANCER CENTER AND ITS AFFILIATES ARE COLLECTIVELY REFERRED TO AS "THE ORGANIZATION". THE CENTER CARRIES ON FUNDRAISING ACTIVITIES ON ITS OWN BEHALF AND ON BEHALF OF THE AFFILIATES. CONTRIBUTIONS AND PLEDGES ARE RECORDED BASED ON THE DONOR'S INTENT IN THE RECORDS OF THE APPROPRIATE ENTITY. FOR 2022, TOTAL CONTRIBUTIONS AND PLEDGES RAISED ON BEHALF OF THE CENTER, HOSPITAL, INSTITUTE AND GRADUATE SCHOOL WERE $452,083,000. CONTRIBUTORS' INFORMATION PROVIDED IN THE ATTACHED SCHEDULE B REPRESENTS THE DONORS' TOTAL PHILANTHROPIC CONTRIBUTIONS TO THE CENTER ONLY. IF ANY DONOR LISTED ON SCHEDULE B MADE CONTRIBUTIONS TO THE HOSPITAL, INSTITUTE, OR GRADUATE SCHOOL, THOSE CONTRIBUTIONS WOULD NOT BE REFLECTED ON THE ATTACHED SCHEDULE B. FUNDRAISING EXPENSES OF $85,128,654 WERE INCURRED AND REPORTED BY THE CENTER IN PART IX, STATEMENT OF FUNCTIONAL EXPENSES. THE CENTER IS ALSO INVOLVED IN LOBBYING FOR THE HOSPITAL AND INSTITUTE, SEE SCHEDULE C. PART II-A. |
| FORM 990, PART VI, LINE 2 | FOR THE TAX YEAR 2022, THE FOLLOWING BUSINESS RELATIONSHIPS WERE REPORTED: 1. DIRECTORS ELLEN V. FUTTER AND PETER J. SOLOMON 2. DIRECTORS ELLEN V. FUTTER AND RICHARD I. BEATTIE FORM 990, PART VI, LINE 11B PRIOR TO FILING THE RETURN, A REVIEW OF THE 990 WAS CONDUCTED BY THE SENIOR VICE PRESIDENT OF FINANCE AND THE CHIEF FINANCIAL OFFICER. IN ADDITION, FORM 990 IS PREPARED IN CONJUNCTION WITH ERNST AND YOUNG, LLP. FORM 990, PART VI, LINE 12C In 2022, MSK's conflict of interest (COI) program was implemented through three comprehensive policies for Memorial Sloan Kettering Cancer Center, Memorial Hospital for Cancer and Allied Diseases and Sloan-Kettering Institute for Cancer Research, which are outlined below: 1. Conflict of Interest and Commitment Policy (the "Individual COI Policy"). a. The Individual COI Policy applied to: (i) physicians and scientists with academic appointments at any level; (ii) any clinical provider who could independently write orders or prescriptions; (iii) individuals whose roles included the design, conduct or reporting of research and/or were engaged in human subject research; (iv) administrative employees with independent authority to make purchasing decisions or who were otherwise able to bind, negotiate on behalf, or execute agreements on behalf of, MSK; and (v) individuals that served on MSK institutional committees with responsibility for oversight of research, formulary, or purchasing decisions. b. MSK's Compliance COI Office ("Compliance") and the institutional conflict of interest committee (the "MSK COI Committee") were responsible for the administration of this policy, under the oversight of the committee of the Board (the "Board COI Committee") dedicated exclusively to discharging the Board's responsibility and authority over MSK's conflicts of interest program. c. Upon becoming covered by the Individual COI Policy, annually thereafter and/or as new significant interests arose, an individual was required to disclose financial interests and external relationships and activities ("interests"), whether paid or unpaid, that reasonably appeared to be related to the individual's institutional responsibilities. Covered Persons were required to disclose interests for themselves and immediate family members. d. Depending on the circumstances and based on established criteria, disclosed interests were reviewed by Compliance, the MSK COI Committee, MSK COI Committee designee(s), and/or the Board COI Committee to determine whether an individual conflict of interest existed or presented the perception thereof (i.e. whether an individual financial interest could directly and significantly impact an individual's institutional responsibilities, or an individual's interest could be directly and significantly impacted by their institutional responsibilities). e. The policy required any individual conflict of interest to be managed, reduced or eliminated. When a conflict of interest determination was made, the MSK COI Committee, the MSK COI Committee designee(s), or the Board COI Committee, as applicable, determined how to address it. For those conflicts deemed manageable, management strategies implemented included disclosure of the interest in relevant publications, presentations, consent forms, and educational materials; recusal and/or other limitation on role; independent oversight by a disinterested senior personnel member or committee; and temporary or permanent reduction, divestiture, relinquishment, or termination of an individual's interest. 2. Institutional Conflict of Interest Policy (the "Institutional COI Policy"). a. The Institutional COI Policy applied to financial interests and relationships ("interests") held by MSK as an institution, as well as those financial interests and relationships ("interests") held by five senior executive officers deemed "Institutional Officials,their immediate family members. Institutional Officials included the President and Chief Executive Officer, the Physician-In-Chief and Chief Medical Officer, the Chief Operating Officer, the Chief Financial Officer, and the Director of the Sloan-Kettering Institute for Cancer Research. b. Institutional interests held by MSK were made available to Compliance through regular reports from and ongoing engagement with relevant MSK departments. Institutional interests held by Institutional Officials were disclosed through the process described above in the Individual COI Policy, as well as the process described below in the Board COI Policy. c. The MSK COI Committee or MSK COI Committee designee(s) were responsible for determining whether an institutional conflict of interest existed; i.e. whether the institutional interest held by MSK or an Institutional Official (or their immediate family members) could, or could reasonably be perceived to, directly and significantly affect the design, conduct, reporting, review, or oversight of MSK research or the outcome of an MSK activity or decision. d. The policy required any institutional conflict of interest to be managed, reduced or eliminated. When an institutional conflict of interest determination was made, the MSK COI Committee and/or the MSK COI Committee designee(s) determined how to address it. For those conflicts deemed manageable, management strategies implemented included recusal of the applicable Institutional Official from decision-making regarding the arrangement and disclosure to relevant personnel; disclosure of the interest in relevant publications, presentations, consent forms, and educational materials; independent oversight by a disinterested senior personnel member or committee; and temporary or permanent reduction, divestiture, relinquishment, or termination of MSK's or an Institutional Official's institutional interest. 3. Boards of Governing Trustees Conflict of Interest Policy (the "Board COI Policy"). a. The Board COI Policy applied to Board members, officers, and other MSK senior leadership. Individuals covered by the Board COI Policy were required to disclose financial interests and relationships, as defined by the policy, annually and on an ongoing basis. Other entities in the same tax-exempt group had overlapping officers and Board members as described in Schedule O; such persons reported financial interests through this or related processes. b. The Board COI Committee was responsible for determining whether any interest disclosed under the Board COI Policy gave rise to a conflict of interest. The policy required that the members of the Board COI Committee vote, without the individual with the potential conflict present, to determine whether a conflict of interest existed. All members participating in the vote were required to be disinterested with respect to the transaction, arrangement, or relationship. c. The covered individual with the conflict of interest could make a presentation to the Board COI Committee, but could not participate in or influence the discussion of, or vote on, the proposed transaction, arrangement, or relationship. The existence and resolution of any conflict of interest, along with associated determinations made and votes taken, were required to be documented in writing. d. For any transaction, arrangement, or relationship that involved a conflict of interest, a conflict management plan could be implemented if doing so was in the best interests of MSK. Management plans could require disclosure, recusal or other limitation of role, independent oversight and confidentiality. |
| FORM 990, PART VI, LINE 15 | MEMORIAL SLOAN-KETTERING CANCER CENTER IS COMMITTED TO ENSURING THAT ITS EXECUTIVE COMPENSATION PROGRAM ADHERES TO THE ESTABLISHED STANDARDS OF REGULATORY COMPLIANCE AND BEST CORPORATE GOVERNANCE. THE BOARD OF TRUSTEES AND GOVERNING TRUSTEES HAS CHARGED THE JOINT HUMAN RESOURCES COMMITTEE (WHICH IS COMPOSED OF INDEPENDENT BOARD MEMBERS WITH NO CONFLICTS OF INTEREST IN REGARD TO EXECUTIVE COMPENSATION) WITH MAKING ALL DECISIONS RELATED TO COMPENSATION FOR OFFICERS AND KEY EMPLOYEES. THE COMMITTEE REVIEWS THE TOTAL COMPENSATION OF THE INDIVIDUALS, INCLUDING BOTH CURRENT AND DEFERRED COMPENSATION, AND ALL EMPLOYEE BENEFITS, ON AN ANNUAL BASIS TO ENSURE THAT THE TOTAL COMPENSATION OF EACH OFFICER AND KEY EMPLOYEE IS REASONABLE. TO ASSIST IN THE COMPLETION OF ITS RESPONSIBILITIES, THE COMMITTEE ENGAGES THE SERVICES OF A NATIONALLY RECOGNIZED CONSULTING FIRM SPECIALIZING IN EXECUTIVE COMPENSATION FOR NOT-FOR-PROFIT HEALTHCARE ORGANIZATIONS. EACH YEAR THE COMMITTEE REVIEWS A COMPREHENSIVE REPORT PREPARED BY THE FIRM THAT INCLUDES MARKET DATA FOR FUNCTIONALLY COMPARABLE ROLES IN COMPARABLE ORGANIZATIONS (I.E., NOT-FOR-PROFIT ACADEMIC/RESEARCH MEDICAL CENTERS, ESPECIALLY THOSE SHARING A MISSION SIMILAR TO MSKCC'S, WITH OTHER HEALTHCARE SECTORS CONSIDERED ON A SELECTED BASIS) AND SUMMARIZES THE RELATIVE MARKET POSITION OF EACH EXECUTIVE'S TOTAL COMPENSATION. THE LAST REVIEW WAS MARCH 2022, WHICH SET THE COMPENSATION FOR THE PERIOD APRIL 2022 TO MARCH 2023. ADDITIONALLY, A SENIOR MEMBER OF THE CONSULTING FIRM ATTENDS THE COMMITTEE'S MEETINGS TO PROVIDE INFORMATION AND TO RESPOND TO QUESTIONS BY THE MEMBERS OF THE COMMITTEE. COMPENSATION LEVELS ARE ESTABLISHED CONSIDERING THE MARKET DATA, AN ASSESSMENT OF PERFORMANCE, AND OTHER BUSINESS JUDGMENT FACTORS, CONSISTENT WITH MSKCC'S EXECUTIVE COMPENSATION PHILOSOPHY. THE COMMITTEE'S DECISIONS ARE MADE IN THE BEST INTERESTS OF MSKCC AND ARE INTENDED TO ENSURE THE RECRUITMENT AND RETENTION OF KEY EXECUTIVE TALENT, CONSISTENT WITH THE MARKET PRACTICES OF OTHER NOT-FOR-PROFIT HEALTHCARE ORGANIZATIONS OF COMPARABLE SCOPE, MISSION AND COMPLEXITY. ON AN ANNUAL BASIS, THE COMMITTEE PROVIDES THE FULL BOARD WITH AN OVERVIEW OF ITS DETERMINATIONS AND PROCESS. THE COMMITTEE'S REVIEW PROCESS FOLLOWS THE INTERMEDIATE SANCTIONS' GUIDELINES FOR QUALIFYING FOR THE REBUTTABLE PRESUMPTION OF REASONABLENESS UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE OF 1986: - THE COMPENSATION ARRANGEMENT IS APPROVED IN ADVANCE BY AN "AUTHORIZED BODY" OF THE APPLICABLE TAX-EXEMPT ORGANIZATION (I.E, THE COMMITTEE, WHICH IS COMPOSED ENTIRELY OF INDIVIDUALS WHO DO NOT HAVE A CONFLICT OF INTEREST WITHIN THE MEANING OF THE REGULATIONS UNDER SECTION 4958). - THE AUTHORIZED BODY OBTAINS AND RELIES UPON "APPROPRIATE DATA AS TO COMPARABILITY" PRIOR TO MAKING ITS DETERMINATION, FOR WHICH COMPARABILITY DATA ARE PROVIDED AND ANALYZED BY SULLIVAN, COTTER AND ASSOCIATES, INC., A WELL-REGARDED EXPERT IN THE AREA OF HEALTHCARE COMPENSATION. THE COMMITTEE ADEQUATELY DOCUMENTS THE BASIS FOR ITS DETERMINATION CONCURRENTLY WITH MAKING THAT DETERMINATION, AGAIN AS REQUIRED IN THE REGULATIONS. |
| FORM 990, PART VI, LINE 19 | THE ORGANIZATION ENGAGED DAC BOND AS ITS INVESTOR RELATIONS AND DISCLOSURE/DISSEMINATION AGENT. AS SUCH COPIES OF THE AUDITED AND QUARTERLY UNAUDITED FINANCIAL STATEMENTS, AND BOND OFFERING STATEMENTS FOR ALL DEBT ISSUES CAN BE ACCESSED AT ITS WEBSITE, WWW.DACBOND.COM. COPIES OF THE ORGANIZATION'S GROUP 990 AND THE AUDITED FINANCIAL STATEMENTS OF MEMORIAL SLOAN-KETTERING CANCER CENTER AND ITS AFFILIATES CAN ALSO BE FOUND AT DAC BONDS. THE CONFLICT-OF-INTEREST POLICY IS ALSO AVAILABLE TO THE PUBLIC UPON REQUEST AND/OR CAN BE FOUND AT THE INSTITUTIONAL WEB SITE: WWW.MSKCC.ORG. GOVERNING DOCUMENTS SUCH AS THE ARTICLES OF INCORPORATION AND CORPORATE BY-LAWS ARE NOT ACCESSIBLE TO THE PUBLIC. FORM 990, PART VII, SECTION B AMOUNTS PAID TO INDEPENDENT CONTRACTORS INCLUDE AMOUNTS FOR SUBCONTRACTORS AS WELL AS REIMBURSABLE EXPENSES. FORM 990, PART XI, LINE 9 CHANGE IN POSTRETIREMENT REVENUE $140,114,000 OTHER NON-OPERATING EXPENSES ($10,091,000) TOTAL-OTHER CHANGES IN NET ASSETS $130,023,000 THE FINANCIAL STATEMENTS OF MEMORIAL SLOAN-KETTERING CANCER CENTER AND ITS AFFILIATES ARE AUDITED BY AN INDEPENDENT ACCOUNTING FIRM ON A COMBINED BASIS. THE COMBINED STATEMENTS INCLUDE THE ACCOUNTS OF THE FOLLOWING TAX EXEMPT, SECTION 501 (C) (3), INCORPORATED AFFILIATES: MEMORIAL SLOAN-KETTERING CANCER CENTER (EIN 13-1924236), MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (EIN 13-1624082), SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (EIN 13-1624182), S.K.I. REALTY, INC. (EIN 13-3389586), LOUIS V. GERSTNER JR., GRADUATE SCHOOL OF BIOMEDICAL SCIENCES (EIN 20-2212588), AND MSK INSURANCE US, INC.(MVI) EIN 83-0363317. INCLUDED IN THE GROUP EXEMPTION IS MSKCC PROPERTIES LLC (EIN 35-2464610) WITH MEMORIAL HOSPITAL BEING THE SOLE MEMBER, AND MSKCC PROTON, INC. (EIN 35-2397819). THE CENTER'S FINANCIAL STATEMENTS ARE NOTAUDITED INDEPENDENT OF THE COMBINED. REFER TO SCHEDULE D FOR A RECONCILIATION OF THE 990 TO THE CENTER'S FINANCIAL STATEMENTS. FINANCIAL STATEMENTS. FINANCIAL STATEMENTS. |
| STRATEGIC PLANNING AND COMMUNITY BENEFITS | MEMORIAL SLOAN-KETTERING CANCER CENTER (MSK) AND ITS AFFILIATES AS REPORTED ON A COMBINED BASIS WITH A SEPARATE GROUP 990 FILING UNDER EIN # 91-2154236. MEMORIAL SLOAN-KETTERING CANCER CENTER AND ITS AFFILIATES ARE INTERTWINED WITH A FINANCIAL ASSISTANCE PROGRAM AND COMMUNITY BENEFIT ACTIVITIES AS OUTLINED BELOW. MSK'S INPATIENT HOSPITAL IS IN MID-MANHATTAN WITH ADDITIONAL OUTPATIENT TREATMENT CENTERS IN BROOKLYN, LONG ISLAND, WESTCHESTER COUNTY, AND NEW JERSEY. OUR PRIMARY CATCHMENT AREA ENCOMPASSES 23 COUNTIES ACROSS THE FIVE BOROUGHS OF NEW YORK CITY, LONG ISLAND, SOUTHERN NEW YORK STATE, NEW JERSEY, AND SOUTHWESTERN CONNECTICUT. A TOTAL OF 214,342 PATIENTS WERE SEEN AT MSK'S FACILITIES IN 2022, INCLUDING 194,242 (90.6 PERCENT) PATIENTS FROM THE TRI-STATE AREA (NY, NJ, CT); 19,010 (8.9 PERCENT) PATIENTS FROM OTHER PARTS OF THE UNITED STATES; AND 1,090 (0.5 PERCENT) PATIENTS FROM OTHER COUNTRIES. THESE PATIENTS ACCOUNTED FOR 24,113 ADMISSIONS TO OUR HOSPITAL WITH 170,076 RELATED PATIENT DAYS AND 686,000 OUTPATIENT VISITS AT OUR COMBINED FACILITIES IN NEW YORK CITY AND THE REGION. SINCE 1987, MSK HAS HAD A FINANCIAL ASSISTANCE PROGRAM (FAP) IN PLACE TO ASSIST UNDERINSURED AND UNINSURED PATIENTS WHO ARE EXPERIENCING DIFFICULTIES MEETING THEIR FINANCIAL RESPONSIBILITIES TO MEMORIAL HOSPITAL AND ITS PHYSICIANS. FINANCIAL COUNSELORS WORK WITH PATIENTS AND INSURANCE COMPANIES INCLUDING MEDICARE AND MEDICAID TO HELP THEM ACCESS SERVICES. THOSE WHO DO NOT QUALIFY FOR PUBLICLY AVAILABLE HEALTH INSURANCE, OR WHO ARE UNABLE TO PAY THEIR PORTION OF FEES ABOVE INSURANCE REIMBURSEMENT, MAY OBTAIN HELP THROUGH THE INSTITUTION'S FAP IF THEY ARE ELIGIBLE. THE INSTITUTION USES A 500% OF THE FEDERAL POVERTY LEVEL (FPL) AS AN ANNUAL INCOME GUIDELINE, TO DETERMINE A PATIENT'S ELIGIBILITY. HOWEVER, A PATIENT MAY QUALIFY FOR FAP EVEN WITH AN INCOME EXCEEDING THE 500% FPL. THAT'S BECAUSE WE ALLOW A DEDUCTION FOR MONTHLY ROUTINE HOUSEHOLD BILLS BASED ON FAMILY SIZE. PATIENTS WITH A ZERO OR NEGATIVE BALANCE ARE THEREFORE, ELIGIBLE FOR THE PROGRAM UNLESS THEY HAVE LARGE ASSETS NOT LINKED TO THEIR RETIREMENT OR EDUCATION. THE TABLE BELOW ALSO ILLUSTRATES THE INCOME GUIDELINE USED IN EVALUATING THE PATIENT'S FINANCIAL STATUS. FAMILY SIZE ALLOWED INCOME RESOURCE LEVELS 1 $ 67,950 $ 42,000 2 $ 91,550 $ 61,500 3 $115,150 $ 62,535 4 $138,750 $ 70,688 5 $162,350 $ 78,848 6 $185,950 $ 87,000 |
| STRATEGIC PLANNING AND COMMUNITY BENEFIT - CONTINUED | MSKCC'S STRATEGIC PLANNING PROCESS INCLUDES DEVELOPING PROGRAMS IN RESPONSE TO CANCER MORBIDITY AND MORTALITY DATA, DEMOGRAPHIC DATA, AND COMMUNITY INPUT IN ACCORDANCE WITH THE IRS COMMUNITY HEALTH NEEDS ASSESSMENTS. THESE FINDINGS ARE USED IN DESIGNING THE IMPLEMENTATION STRATEGY TO PLAN INITIATIVES AND PROGRAMS AIMED AT IMPROVING OUR COMMUNITIES' ACCESS TO CANCER INFORMATION AND CANCER CARE. THE ORGANIZATION'S STRATEGIC EFFORTS ARE ALSO FOCUSED ON REDUCING THE CRITICAL ISSUE OF CANCER HEALTH DISPARITIES AMONG MINORITY AND MEDICALLY UNDERSERVED POPULATIONS. THESE PROGRAM SERVICES ARE OFFERED THROUGH VARIOUS CHANNELS WITHIN THE INSTITUTION. THE MSK RALPH LAUREN CENTER (RLC), PROVIDES CANCER PREVENTION, SCREENING, DIAGNOSIS, AND TREATMENT AS WELL AS SOCIAL SERVICES, FINANCIAL COUNSELING AND A FOOD PANTRY SUPPLEMENTED WITH NUTRITIONAL COUNSELING. RLC'S SCOPE OF SERVICES INCLUDE BREAST CANCER EVALUATION, DIAGNOSTIC AND TREATMENT SERVICES, INCLUDING CHEMOTHERAPY, FOR MOST CANCERS AND BLOOD DISEASES, AND SCREENING SERVICES FOR BREAST, CERVICAL, COLON, PROSTATE AND LUNG CANCER AND SMOKING CESSATION PROGRAM. RLC IS STAFFED BY MEDICAL ONCOLOGISTS, A BREAST SURGEON, APP'S, REGISTERED NURSES, PATIENT CARE TECHNICIANS, A DIETICIAN/NUTRITIONIST, RADIOLOGY TECHNOLOGISTS, AND LAB TECHNICIANS. REFERRALS TO CLINICIANS, PROGRAMS, AND FACILITIES WITHIN MEMORIAL HOSPITAL ARE COORDINATED FOR PATIENTS REQUIRING SUCH SERVICES. TO-DATE RLC HAS MANAGED MORE THAN 186,000 PATIENT VISITS. THE PSYCHIATRY & BEHAVIORAL SERVICES DEPARTMENT'S PSYCHIATRISTS AND PSYCHOLOGISTS USE THEIR EXPERTISE TO ASSIST PATIENTS WITH THE SPECTRUM OF PSYCHIATRIC AND BEHAVIORAL ISSUES THAT ARISE DURING DIAGNOSIS AND TREATMENT. THE DEPARTMENT ALSO WORKS TO DEEPEN ITS UNDERSTANDING AND EXPAND TREATMENT OPTIONS FOR ONCOLOGY PATIENTS AROUND THE GLOBE THROUGH CLINICAL TRIALS, RESEARCH, AND OTHER MEANS. THE DEPARTMENT OFFERS INPATIENT AND OUTPATIENT PSYCHOLOGICAL AND SOCIAL SUPPORT SERVICES TO PATIENTS, THEIR FAMILIES, AND CAREGIVERS. SERVICES PROVIDED INCLUDE CONSULTATIONS AND EVALUATION, PSYCHOTHERAPY, MEDICATION MANAGEMENT AND PHARMACOTHERAPY, SUPPORTIVE COUNSELING, SMOKING CESSATION, HYPNOTHERAPY, AND VARIOUS DIAGNOSTIC TESTS, AND OTHERS. DURING 2022, THE DEPARTMENT EXPERIENCED 27,216 INPATIENT AND OUTPATIENT ENCOUNTERS WITH 1,996 PATIENTS TREATED THROUGH THE SMOKING CESSATION PROGRAM. APPROXIMATELY $5.00M WAS EXPENDED BY THE DEPARTMENT TO SUPPORT ITS COMMUNITY BENEFIT-RELATED PROGRAMS. AT MSK WE BELIEVE IN CARING FOR THE WHOLE PERSON NOT JUST THE DISEASE OR SYMPTOM. INTEGRATIVE MEDICINE WEAVES NATURAL TREATMENTS SUCH AS ACUPUNCTURE, MASSAGE, AND YOGA INTO OUR OVERALL CARE PLAN. ALL OF OUR HOLISTIC HEALTH SERVICES AND PROGRAMS ARE BASED ON THE LATEST SCIENTIFIC EVIDENCE. THE INTEGRATIVE MEDICINE SERVICE PROVIDES FREE CLINICAL CARE FOR INPATIENTS. DURING 2022, THE DEPARTMENT SERVICED 6,656 PATIENT VISITS. THESE CLINICAL SERVICES INCLUDED MUSIC THERAPY, TOUCH THERAPY, ACUPUNCTURE, YOGA AND YOGIC BREATHING, MEDITATION AND GUIDED IMAGERY, KARATE AND DANCE THERAPY. WE ALSO PROVIDED EXTENSIVE EDUCATION FOR PATIENTS AND CAREGIVERS DURING BEDSIDE AND GROUP VISITS. IN ADDITION, WE OFFER OUTPATIENT ACUPUNCTURE CONSULTATIONS TO ANYONE IN THE COMMUNITY AT NO COST TO THEM. THESE CONSULTATIONS ADVISED CLIENTS ON HOW ACUPUNCTURE COULD BENEFIT THEIR CONDITION BASED ON THEIR SPECIFIC THERAPEUTIC NEEDS. THERE WERE 87 ACUPUNCTURE CONSULTATIONS PROVIDED IN 2022. THE DEPARTMENT INCURRED $1.11M IN PERSONNEL COST TO DELIVER COMMUNITY BENEFIT-RELATED PROGRAMS. MSK ENGAGES IN AND SUPPORTS COALITION-BUILDING ACTIVITIES THAT PROMOTE THE HEALTH OF THE COMMUNITY'S IT SERVES. STAFF MEMBERS ARE ENCOURAGED TO SHARE THEIR CLINICAL EXPERTISE AND EXPERIENCE WITH PARTNERING HEALTHCARE FACILITIES AND COMMUNITY ORGANIZATIONS. STAFF SERVE AND PARTICIPATE IN NUMEROUS COMMUNITY GROUPS INCLUDING THE AMERICAN CANCER SOCIETY, THE GREATER NEW YORK HOSPITAL ASSOCIATION, AND MANY HEALTH IMPROVEMENT ADVOCACY GROUPS FOR VARIOUS TYPES OF CANCER. FOR INSTANCE, MSK SPONSORS SEVERAL PROGRAMS THAT GIVE MEDICAL STUDENTS, UNDERGRADUATES, AND HIGH SCHOOL STUDENTS THE OPPORTUNITY TO WORK AT THE INSTITUTION DOING CLINICAL AND LABORATORY RESEARCH. THROUGH THESE PROGRAMS, MEMORIAL SLOAN KETTERING STRIVES TO INCREASE THE PIPELINE OF SCIENTISTS AND PHYSICIANS WORKING IN ONCOLOGY. IN 2021, THE ORGANIZATION ESTABLISHED THE OFFICE OF HEALTH EQUITY (OHE) TO ADDRESS CANCER DISPARITIES THAT EXIST DUE TO RACIAL, ETHNIC, CULTURAL, OR SOCIOECONOMIC BARRIERS. THROUGH A PATIENT CENTRIC FOCUS, THE OHE IS RESPONSIBLE FOR LEADING PATIENT CARE AND RESEARCH ACTIVITIES INCLUDING THE CANCER HEALTH EQUITY RESEARCH PROGRAM (CHERP) AND CANCER EQUITY PROGRAMS. INTEGRAL TO OHE'S ROLE IS THE DEVELOPMENT OF HEALTH EQUITY RESEARCH AND EDUCATION AND TRAINING. AS SUCH THE OHE HAS IMPLEMENTED RECRUITING AND TRAINING INITIATIVES ACROSS THE INSTITUTION. THE OBJECTIVE OF THESE TRAINING PROGRAMS IS TO ENHANCE THE DIVERSITY OF FUTURE CANCER RESEARCH WORKFORCE BY PROVIDING MINORITY STUDENTS WITH EXPOSURE TO CUTTING-EDGE CANCER RESEARCH WITH RENOWNED MENTORS. OUR BASIC AND TRANSLATIONAL RESEARCHERS HAVE MADE MANY SIGNIFICANT CONTRIBUTIONS TO THE SCIENTIFIC COMMUNITY'S UNDERSTANDING OF CANCER BIOLOGY AND CANCER GENETICS AS WELL AS TO RELATED FIELDS OF VARIOUS TYPES OF BIOLOGY AND DRUG DEVELOPMENT. GENES FIRST IDENTIFIED IN OUR LABORATORIES ARE NOW THE FOCUS OF INTENSE RESEARCH IN OTHER LABORATORIES AROUND THE WORLD. DRUGS, MONOCLONAL ANTIBODIES, AND OTHER AGENTS FIRST DEVELOPED IN OUR LABORATORIES HAVE GONE ON TO GAIN REGULATORY APPROVAL FOR TREATING PATIENTS WORLDWIDE. RECENT EXPANSION OF OUR LABORATORY SPACE HAS ALLOWED US TO GROW OUR RESEARCH EFFORTS SO THAT GOING FORWARD WE CAN CONTINUE TO MAKE DISCOVERIES THAT WILL CHANGE THE WAY THE WORLD UNDERSTANDS CANCER AND AID IN THE DEVELOPMENT OF BETTER TREATMENTS FOR CANCER PATIENTS EVERYWHERE. IN 2022, MEMORIAL SLOAN KETTERING SPENT $755.90M IN SUPPORT OF ITS RESEARCH MISSION, OF WHICH $241.20M WAS SPONSORED BY GOVERNMENTAL AND OTHER NON-PROFIT ORGANIZATIONS, $154.82M FROM PHILANTHROPY, AND $359.63M FROM THE INSTITUTION'S FUNDS. |
| STRATEGIC PLANNING AND COMMUNITY BENEFITS - CONTINUED | EDUCATION AND TRAINING ARE KEY COMPONENTS OF MEMORIAL SLOAN KETTERING'S MISSION AND IMPORTANT EXAMPLES OF HOW THE INSTITUTION MAKES CONTRIBUTIONS TO THE CARE AND TREATMENT OF CANCER PATIENTS FAR BEYOND ITS OWN WALLS THROUGH WORKFORCE DEVELOPMENT. OUR TRAINING, GRADUATE, AND CONTINUING EDUCATION PROGRAMS PREPARE PHYSICIANS, SCIENTISTS, NURSES, AND TECHNICIANS TO BE LEADERS IN THEIR CHOSEN FIELDS. THESE HEALTHCARE PROVIDERS CAN THEN TAKE THE EXPERTISE GAINED FROM WORKING WITH OUR SPECIALISTS TO OTHER HEALTHCARE INSTITUTIONS AROUND THE COUNTRY AND THROUGHOUT THE WORLD. MSK ALSO TRAINS GRADUATE STUDENTS AND POSTDOCTORAL RESEARCHERS WORKING IN MANY AREAS OF BASIC SCIENCE AND TRANSLATIONAL RESEARCH. WHEN THESE YOUNG SCIENTISTS COMPLETE THEIR TRAINING,THEY BRING THE SKILLS OBTAINED IN OUR LABORATORIES INTO THE ACADEMIC COMMUNITY AT LARGE AS WELL AS THE PRIVATE SECTOR. MEMORIAL SLOAN KETTERING UTILIZED $237.09M OF THE INSTITUTION'S RESOURCES DURING 2022 TO SUPPORT ITS EDUCATION AND TRAINING MISSION, WHICH WE CONSIDER VITAL, GIVEN OUR LEADERSHIP ROLE IN CANCER CARE TREATMENT AND RESEARCH. $55.71M OF THE AMOUNT WAS SPONSORED BY GOVERNMENTAL AND OTHER REVENUE SOURCES AND $181.38M FROM THE INSTITUTION'S GENERAL FUND. COVID-19 THROUGHOUT THE COVID-19 PANDEMIC AND BEYOND MSK CONTINUES TO WORK TO PROTECT AND ASSIST THE PUBLIC. CURRENTLY, THE INSTITUTION IS ACTIVELY MAINTAINING A POSTURE OF PREVENTION AND SAFETY, WITH ITS EDUCATION PROGRAMS WHILE ENCOURAGING PERSONS TO WEAR THEIR MASKS AND ADHERE TO OTHER PREVENTIVE MEASURES LIKE GETTING BOOSTER SHOTS. EXPANDING OUR PRESENCE IN 2022 THE INSTITUTION THROUGH ITS PHYSICIAN PRACTICE GROUP - MEMORIAL MEDICAL CARE PC. ENTERED INTO AN AGREEMENT TO OPEN A FACILITY IN THE HEART OF BROOKLYN; BRINGING MSK'S WORLD-CLASS CANCER CARE DIRECTLY TO A BROADER PATIENT POPULATION, ENSURING GREATER ACCESS AND EQUITY TO PEOPLE IN BROOKLYN, QUEENS, AND THE BROADER NEW YORK METRO AREA AT A LOCATION THAT IS CLOSER TO HOME. WORKING ALONGSIDE THE NEW YORK CANCER & BLOOD SPECIALISTS TEAM, PATIENTS WILL HAVE ACCESS TO A WIDE RANGE OF SERVICES, INCLUDING ADVANCED IMAGING, STATE-OF-THE-ART THERAPIES, CUTTING-EDGE CLINICAL TRIALS, AND A MULTIDISCIPLINARY TEAM OF SPECIALISTS PROVIDING COLLABORATIVE PATIENT CARE AND DELIVERING THE BEST POSSIBLE OUTCOMES. PATIENTS REQUIRING COMPLEX CANCER CARE AND SURGERY WILL HAVE DIRECT ACCESS TO MSK'S MAIN HOSPITAL IN MANHATTAN. |
| Software ID: | |
| Software Version: |